U.S. markets closed

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
107.73-0.35 (-0.32%)
At close: 4:03PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close108.08
Open107.50
Bid107.30 x 800
Ask107.75 x 800
Day's Range107.10 - 108.25
52 Week Range79.11 - 121.53
Volume12,174,943
Avg. Volume7,010,038
Market Cap190.378B
Beta (5Y Monthly)0.79
PE Ratio (TTM)29.05
EPS (TTM)3.71
Earnings DateOct 28, 2021 - Nov 01, 2021
Forward Dividend & Yield5.20 (4.83%)
Ex-Dividend DateOct 14, 2021
1y Target Est125.96
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-24% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • AbbVie Inc.
    Analyst Report: AbbVie Inc.AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
    Rating
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • Motley Fool

    Is AbbVie a Bad News Buy?

    The U.S. Food and Drug Administration recently announced restrictions on JAK inhibitors that hurt AbbVie's (NYSE: ABBV) prospects for autoimmune disease drug Rinvoq. AbbVie stock sank more than 10% after the FDA's decision. In this Motley Fool Live video recorded on Sept. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie stock is now a bad news buy.

  • TheStreet.com

    Cramer: Using Short-Term Moves to Tweak Your Portfolio

    Whether the news is good or bad, you can take advantage of it if you understand why you're involved in a stock in the first place.

  • Motley Fool

    AbbVie's Pain Is Sanofi's and Regeneron's Gain

    There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors.